Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Cze-Ci Chan"'
Publikováno v:
Annals of Intensive Care, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Background Acute heart failure is a life-threatening clinical condition. Levosimendan is an effective inotropic agent used to maintain cardiac output, but its usage is limited by the lack of evidence in patients with severely abnormal renal
Externí odkaz:
https://doaj.org/article/85338f0e53ce4f06ae9a8f50b2a76182
Autor:
Ann Wan-Chin Ling, Cze-Ci Chan, Shao-Wei Chen, Yi-Wei Kao, Chien-Ying Huang, Yi-Hsin Chan, Pao-Hsien Chu
Publikováno v:
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-12 (2020)
Abstract Background Sodium glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of hard cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without established cardiovascular diseases. Whether SGLT2i is associated with a
Externí odkaz:
https://doaj.org/article/283e69db85d740a1b39c6b2ff0debdfb
Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation
Autor:
Yi-Hsin Chan, Chi Chuang, Cze-Ci Chan, Hsin-Fu Lee, Ya-Chi Huang, Yu-Tung Huang, Shang-Hung Chang, Chun-Li Wang, Tze-Fan Chao, Chi-Tai Kuo, Yung-Hsin Yeh, Shih-Ann Chen
Publikováno v:
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-14 (2020)
Abstract Background Studies specifically examining the association between glycated hemoglobin A1c (HbA1c) levels and ischemic stroke/systemic thromboembolism (IS/SE) risk in atrial fibrillation (AF) patients are limited. Here, we investigated the as
Externí odkaz:
https://doaj.org/article/0a100653ff094ea6a9b9cc13d0125a26
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 9, Pp 1594-1605 (2023)
Abstract Skepticism exists among healthcare workers and patients regarding the efficacy and safety of generic medication, despite its potential to lower healthcare costs. This study aimed to compare the outcomes of a generic clopidogrel and its brand
Externí odkaz:
https://doaj.org/article/ca02031932934c8c84d61d7aaf25f736
Publikováno v:
Frontiers in Cardiovascular Medicine. 9
Since 2020, new vaccines were developed to fight the coronavirus disease 2019 (COVID-19). Vaccination is important in preventing mortality and achieving herd immunity. However, due to vast vaccination, fatal adverse events could be seen. We report a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a380426699e58a0c186323a9e09e9527
https://doi.org/10.3389/fcvm.2022.1014250
https://doi.org/10.3389/fcvm.2022.1014250
Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation
Autor:
Tze-Fan Chao, Cze-Ci Chan, Chi Chuang, Shang-Hung Chang, Ya-Chi Huang, Chun-Li Wang, Yu-Tung Huang, Chi-Tai Kuo, Shih Ann Chen, Yung-Hsin Yeh, Hsin-Fu Lee, Yi-Hsin Chan
Publikováno v:
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-14 (2020)
Cardiovascular Diabetology
Cardiovascular Diabetology
BackgroundStudies specifically examining the association between glycated hemoglobin A1c (HbA1c) levels and ischemic stroke/systemic thromboembolism (IS/SE) risk in atrial fibrillation (AF) patients are limited. Here, we investigated the association
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eac96b611ec75ef259f4196367d9a91b
http://link.springer.com/article/10.1186/s12933-020-01005-8
http://link.springer.com/article/10.1186/s12933-020-01005-8
Autor:
Shao-Wei Chen, Ann Wan-Chin Ling, Cze-Ci Chan, Yi-Wei Kao, Chien-Ying Huang, Pao-Hsien Chu, Yi-Hsin Chan
Publikováno v:
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-12 (2020)
Cardiovascular Diabetology
Cardiovascular Diabetology
BackgroundSodium glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of hard cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without established cardiovascular diseases. Whether SGLT2i is associated with a lower risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e25d993d6fe1cc3f18e2b2eeca38e5
https://doi.org/10.21203/rs.3.rs-31689/v2
https://doi.org/10.21203/rs.3.rs-31689/v2
Publikováno v:
Annals of Intensive Care
Annals of Intensive Care, Vol 11, Iss 1, Pp 1-11 (2021)
Annals of Intensive Care, Vol 11, Iss 1, Pp 1-11 (2021)
Background Acute heart failure is a life-threatening clinical condition. Levosimendan is an effective inotropic agent used to maintain cardiac output, but its usage is limited by the lack of evidence in patients with severely abnormal renal function.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e7199d7bc1e0c1d80f305b5fc94ea0a
https://pubmed.ncbi.nlm.nih.gov/33555483
https://pubmed.ncbi.nlm.nih.gov/33555483
Autor:
Ling, Ann Wan-Chin, Cze-Ci Chan, Chen, Shao-Wei, Kao, Yi-Wei, Huang, Chien-Ying, Chan, Yi-Hsin, Pao-Hsien Chu
Additional file 1: Table S1. The ATC code of SGLT2i and DPP4i. Table S2. Clinical characteristics of the patients with type 2 diabetes treated with SGLT2i and DPP4i before and after 1:1 propensity score matching (PSM).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27db1bb56ee3ec2d6a1cb5f609aa315b